(288) Risk Factors and Real-World Short-Term Outcomes of a Failed Trial of Void After Rezum in a Multiethnic Population

Abstract Introduction A failed trial of void (TOV) following surgery for benign prostatic hyperplasia (BPH) predisposes patients to have trouble voiding, increases hospital stays and office visits, detrusor muscle injury due bladder over-distention. Rezum is a minimally invasive surgical therapy that utilizes convective radiofrequency water vapor thermal energy ablate obstructive lobes the prostate, resulting in improvement lower urinary tract symptoms (LUTS) secondary BPH. Identifying risk factors TOV can help identify group BPH who may need be counseled preoperatively an increased postoperative retention therefore their period catheterization extended. Objective The purpose study was assess impact on real-world short-term outcomes. Methods single office, retrospective conducted treated with between December 2017 October 2019. Patients were included if they had follow-up catheter removal after Rezum. excluded requiring day procedure. placed all treatment. Demographic data outcome measures, including International Prostate Symptom Score (IPSS), quality life (QoL), Index Erectile Function (IIEF)-Erectile -Orgasmic function, maximum flow rate (Qmax), postvoid residual (PVR), adverse events analyzed at baseline, 1-, 3-, and/or 6-months postoperatively. Risk identified through multivariate logistic regression analyses. Results total 289 included, majority being Asian (36.0%), followed by non-Hispanic Black (28.7%), Hispanic (22.5%), White (12.8%). Thirty-five (12.1%) while 254 (87.9%) successful TOV. All given median 5 days (4-5). Those spent mean 13.7 (SD: 13.3) catheter. more likely get infection (20.0% vs. 4.7%, p 200 ml (40.0%) when compared baseline PVR <200 (10.9%, p=0.008). Conclusions Following Rezum, approximately 1 8 not able pass initial Baseline only independent factor Nevertheless, experienced significant relief LUTS preservation sexual function. large PVR, particularly >200 ml, should possibly failing extended period. These also alternative treatment options which better candidate for. Disclosure No